$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Encephalomyelitis - Pipeline Review, H2 2018 [Report Updated: 14-08-2018]

Published by Global Markets Direct: 14 Aug 2018 | 217970 | In Stock

Introduction

Encephalomyelitis - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H2 2018, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape.

Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalomyelitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, IND/CTA Filed and Preclinical stages are 1, 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Encephalomyelitis - Pipeline Review, H2 2018 [Report Updated: 14-08-2018]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Encephalomyelitis - Overview

    Encephalomyelitis - Therapeutics Development

    Pipeline Overview

    Pipeline by Companies

    Pipeline by Universities/Institutes

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Encephalomyelitis - Therapeutics Assessment

    Assessment by Target

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Encephalomyelitis - Companies Involved in Therapeutics Development

    Astellas Pharma Inc

    Aurigene Discovery Technologies Ltd

    Biovista Inc

    Hemispherx Biopharma Inc

    Inflazome Ltd

    Johnson & Johnson

    K-Pax Pharmaceuticals Inc

    Philogen SpA

    Encephalomyelitis - Drug Profiles

    ASP-4058 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    FR-104 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    JM-4 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    KPAX-002 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MCC-950 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    nonathymulin - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    rintatolimod - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule for Chronic Fatigue Syndrome - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    tetravil - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    WEHI-345 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Encephalomyelitis - Dormant Projects

    Encephalomyelitis - Product Development Milestones

    Featured News & Press Releases

    Apr 24, 2018: New Hope for Patients with Mylagic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

217970 | GMDHC10691IDB

Number of Pages

56

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Encephalomyelitis - Pipeline Review, H1 2018
Encephalomyelitis - Pipeline Review, H1 2018SummaryGlobal Markets Direct's latest Pharmaceutical and...
20 Feb 2018 by Global Markets Direct USD $2,000 More Info
Encephalomyelitis - Pipeline Review, H2 2017
Encephalomyelitis - Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and...
16 Aug 2017 by Global Markets Direct USD $2,000 More Info
Encephalomyelitis Global Clinical Trials Review, H2, 2017
Encephalomyelitis Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial report, ...
11 Aug 2017 by Global Data USD $2,500 More Info
Poultry Diagnostics Market by Test (ELISA, PCR) Disease (Avian Salmonellosis, Avian Influenza, Newcastle Disease, Avian Pasteurellosis, Encephalomyelitis, Infectious Bronchitis), Service (Virology, Bacteriology, Parasitology) - Global Forecast to 2022
The global poultry diagnostics market is estimated to grow at a CAGR of 10.5%, to reach USD 495.3 mi...
09 May 2017 by MarketsandMarkets USD $5,650 More Info
Encephalomyelitis - Pipeline Review, H1 2017
Encephalomyelitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and...
15 Mar 2017 by Global Markets Direct USD $2,000 More Info
Encephalomyelitis Global Clinical Trials Review, H1, 2016
Encephalomyelitis Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, ...
30 Jun 2016 by Global Data USD $2,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Encephalomyelitis - Pipeline Review, H2 2018 [Report Updated: 14-08-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data